Entries by Stijn van den Borne, MSc

Navigating HER2 Testing: Unveiling the Strengths and Limitations to Optimize Biomarker Assessment

/in , /by

Due to the availability of human epidermal growth factor receptor 2 (HER2)-directed therapies, testing for HER2 alterations, including overexpression, gene amplification or mutations is recommended in treatment guidelines for various tumor types, including breast cancer, gastric cancer, biliary tract cancer, cervical cancer, colorectal cancer, non-small cell lung cancer (NSCLC), and others.1-10

Prevalence and role of HER2 driver mutations in cancers

/in /by

Apart from Human Epidermal Growth Factor Receptor 2 (HER2) gene amplification or receptor protein overexpression (discussed in Article 1 and Article 3), dysregulation of HER2 activity may also be caused by HER2 gene mutations.1 Approximately 90% of the mutations are clustered in the extracellular dimerization domain and intracellular kinase domain, with the remainder occurring within the juxtamembrane or transmembrane domains.

Decoding HER2 IHC Scoring Guidelines: Understanding Immunohistochemistry Scoring in Different Cancers

/in /by

Human Epidermal Growth Factor Receptor 2 (HER2) aberrations, such as overexpression, HER2 gene amplification, and HER2 mutations, have been extensively researched and are associated with tumor proliferation in various solid tumor types including breast cancer, gastric cancer, gastroesophageal junction (GEJ) cancer, biliary tract cancer, colorectal cancer (CRC), non-small cell lung cancer (NSCLC), and bladder cancer.1 The presence of HER2 aberrations is linked to reduced survival, increased chance of brain metastasis, and treatment resistance.2

US FDA approved immune-checkpoint inhibitors updated 08-Dec-2020

/19 Comments/in , , , , , , , , , , /by

Know all the United States Food and Drug Administration (U.S. FDA) approved immune-checkpoint inhibitors. Members of MediPaper can download the free PPT slides summarising the U.S. FDA approved immune-checkpoint inhibitors and other U.S. FDA approved immunotherapies.